Genomic Health Inc (GHDX)

29.59
0.07 0.24
NASDAQ : Health Care
Prev Close 29.52
Open 29.51
Day Low/High 29.05 / 29.88
52 Wk Low/High 20.05 / 35.79
Volume 93.38K
Avg Volume 117.20K
Exchange NASDAQ
Shares Outstanding 34.34M
Market Cap 1.03B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Genomic Health Announces Upcoming Presentation Of Four Oncotype DX® Studies Including New Validation On Its Ability To Predict Prostate Cancer-specific Death And Metastases

Genomic Health Announces Upcoming Presentation Of Four Oncotype DX® Studies Including New Validation On Its Ability To Predict Prostate Cancer-specific Death And Metastases

Data from American Urological Association 2017 Annual Meeting Establishes Oncotype DX as First Genomic Prostate Cancer Test to Predict Both Near-term Adverse Pathology and Long-term Outcomes

Oncotype DX® Predicts 10-year Risk Of Developing Metastatic Prostate Cancer In Low- And Intermediate-risk Patients

Oncotype DX® Predicts 10-year Risk Of Developing Metastatic Prostate Cancer In Low- And Intermediate-risk Patients

Designated One of the 'Best Posters' by EAU, Results Highlight Expanded Value of Genomic Prostate Score™ in Assessing Risk and Long-term Outcomes in Patients Across Stages of Disease

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Published Outcomes Results From SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based On Oncotype DX® Results

Published Outcomes Results From SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based On Oncotype DX® Results

A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low Oncotype DX Breast Recurrence Score® Results

Multiple Presentations At 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact Of Oncotype DX Breast Recurrence Score® In Reducing Burden And Cost Of Chemotherapy

Multiple Presentations At 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact Of Oncotype DX Breast Recurrence Score® In Reducing Burden And Cost Of Chemotherapy

New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy Decisions in Node-negative and Node-positive Disease and Support Growing Adoption of Test

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALLY, CENX, DEL, DK, FWRD, GHDX, GWW, MLNX, QUAD, TSLX, WFM, WIRE Downgrades: AIMC, FTR, TRN Initiations: ACBI Read on to get TheStreet Quant Ratings' detailed report:

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Four New Studies Of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value Of Test In Guiding Early-stage Prostate Cancer Risk Assessment And Treatment Selection

Four New Studies Of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value Of Test In Guiding Early-stage Prostate Cancer Risk Assessment And Treatment Selection

Presentations at 2017 ASCO Genitourinary Cancers Symposium in Orlando, Feb. 16-18, Underscore Test's Clinical Utility in Low- and Intermediate-risk Patients

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Announces Inclusion Of Oncotype DX® In The 8th Edition Of American Joint Committee On Cancer (AJCC) Criteria For Breast Cancer Staging

Genomic Health Announces Inclusion Of Oncotype DX® In The 8th Edition Of American Joint Committee On Cancer (AJCC) Criteria For Breast Cancer Staging

For the First Time, AJCC Adds Molecular Markers to Staging Criteria, Including Oncotype DX along with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 Status

Genomic Health Announces Results From Multiple Oncotype DX® Studies, Reinforcing Its Impact In Delivering Precision Medicine To Breast Cancer Patients Around The World

Genomic Health Announces Results From Multiple Oncotype DX® Studies, Reinforcing Its Impact In Delivering Precision Medicine To Breast Cancer Patients Around The World

Presentations at 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) Highlight Unique Value of Oncotype DX in Tailoring Treatment Across the Breast Cancer Patient Journey

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.94, changing hands for $32.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk Of Metastasis And Mortality

Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk Of Metastasis And Mortality

Oncotype DX® Genomic Prostate Score™ Becomes Only Test Validated to Measure All Four Critical Features of Tumor Aggressiveness

Comprehensive Economic Analysis Published In Reviews In Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads To Substantial Cost Savings And Increase In Active Surveillance

Comprehensive Economic Analysis Published In Reviews In Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads To Substantial Cost Savings And Increase In Active Surveillance

Unique Prospective Study Provides Real-world Evidence Demonstrating Use of Oncotype DX® Genomic Prostate Score™ Saves Over $2,000 per Patient by Optimizing Care and Healthcare Spending

Genomic Health Presents Robust Analytical Validation Study Results Of Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Presents Robust Analytical Validation Study Results Of Oncotype SEQ™ Liquid Biopsy Mutation Panel

Data Presented for First Time at ESMO 2016 Congress Highlight Company's Commitment to Delivering Rigorous, Clinically Actionable Liquid-based Tests for Late-stage Cancer Patients

Multiple Oncotype DX® Presentations At ESMO 2016 Congress Reinforce Its Unique Clinical Utility With Prospective Outcomes Results In Over 63,000 Breast Cancer Patients

Multiple Oncotype DX® Presentations At ESMO 2016 Congress Reinforce Its Unique Clinical Utility With Prospective Outcomes Results In Over 63,000 Breast Cancer Patients

Two Large International Studies Underscore Ability of Oncotype DX to Identify Patients with Node-positive Breast Cancer Who Can Forego Chemotherapy and Its Side Effects

Genomic Health Reinforces Global Leadership In Genomic-based Diagnostics With Presentation Of Nine Personalized Medicine Studies Conducted In Six Countries At ESMO 2016 Congress

Genomic Health Reinforces Global Leadership In Genomic-based Diagnostics With Presentation Of Nine Personalized Medicine Studies Conducted In Six Countries At ESMO 2016 Congress

Broad Range of Presentations Includes Oncotype SEQ™ Liquid Biopsy Analytical Validation, New Outcomes Data in Invasive Breast Cancer and Studies in Node-positive Disease

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.